Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Precision BioSciences, Inc is a biotechnology business based in the US. Precision BioSciences shares (DTIL) are listed on the NASDAQ and all prices are listed in US Dollars. Precision BioSciences employs 220 staff and has a trailing 12-month revenue of around USD$19.5 million.
Since the stock market crash in March caused by coronavirus, Precision BioSciences's share price has had significant positive movement.
Its last market close was USD$9.54, which is 16.04% up on its pre-crash value of USD$8.01 and 91.18% up on the lowest point reached during the March crash when the shares fell as low as USD$4.99.
If you had bought USD$1,000 worth of Precision BioSciences shares at the start of February 2020, those shares would have been worth USD$688.54 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,160.54.
|Latest market close||USD$9.54|
|52-week range||USD$4.6 - USD$23.6702|
|50-day moving average||USD$6.0141|
|200-day moving average||USD$6.9362|
|Wall St. target price||USD$17.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.124|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||-11.01%|
|1 month (2020-10-30)||51.19%|
|3 months (2020-08-28)||70.36%|
|6 months (2020-05-29)||36.09%|
|1 year (2019-11-29)||-46.31%|
|2 years (2018-11-26)||N/A|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Revenue TTM||USD$19.5 million|
|Gross profit TTM||USD$22.2 million|
|Return on assets TTM||-28.54%|
|Return on equity TTM||-77.97%|
|Market capitalisation||USD$357 million|
TTM: trailing 12 months
There are currently 2.8 million Precision BioSciences shares held short by investors – that's known as Precision BioSciences's "short interest". This figure is 29.8% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting Precision BioSciences shares can be evaluated.
Precision BioSciences's "short interest ratio" (SIR) is the quantity of Precision BioSciences shares currently shorted divided by the average quantity of Precision BioSciences shares traded daily (recently around 866245.0617284). Precision BioSciences's SIR currently stands at 3.24. In other words for every 100,000 Precision BioSciences shares traded daily on the market, roughly 3240 shares are currently held short.
However Precision BioSciences's short interest can also be evaluated against the total number of Precision BioSciences shares, or, against the total number of tradable Precision BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Precision BioSciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Precision BioSciences shares in existence, roughly 50 shares are currently held short) or 0.0608% of the tradable shares (for every 100,000 tradable Precision BioSciences shares, roughly 61 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Precision BioSciences.
Find out more about how you can short Precision BioSciences stock.
We're not expecting Precision BioSciences to pay a dividend over the next 12 months.
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.